Solventum (SOLV)

NYSE Health Care Health Care Technology S&P 500
$90.38
+3.20 (+3.67%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Last report (Nov 05)
$1.45 vs $1.35 est.
Surprise +7.4%

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Nov 05, 2026Sep/2026$1.35$1.45+7.4%

Our record of SOLV's reports since we began tracking; it grows each quarter.

Latest results, in brief

All SOLV 8-K briefs →
Nov 5, 4:07 PM ET

Solventum Reports Q3 2026 Results, Raises Full-Year Adjusted EPS Guidance to $7.20–$7.30

Mixed earnings 2.02

Solventum reported third-quarter 2026 net sales of $1.9 billion, a 7.0 percent decrease on a reported basis due to prior-quarter advance orders placed ahead of ERP cutovers. Despite the sales decline and a GAAP net loss of $12 million, the company raised its full-year adjusted diluted EPS guidance to a range of $7.20 to $7.30 and expects organic sales growth toward the high end of its +2.5% to +3.0% range.

  • Q3 2026 net sales were $1.9 billion, reflecting a 7.0% reported decrease and a 2.8% organic decrease.
  • GAAP diluted earnings per share was $(0.07), while adjusted diluted earnings per share was $1.45.
  • Full-year adjusted EPS guidance was raised to $7.20 to $7.30 from the prior range of $7.10 to $7.20.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$1.95B-7.0% $-0.07-101.0% -$12.00M-0.6%
Jun 2026$2.21B+2.2% $0.53+3.9% $92.00M4.2%
Mar 2026$2.01B-3.0% $0.07-91.0% $13.00M0.6%
Dec 2025$2.00B-3.7% $0.35+94.4% $63.00M3.2%
Sep 2025$2.10B+0.7% $7.22+931.4% $1.27B60.4%
Jun 2025$2.16B+3.8% $0.51+0.0% $90.00M4.2%
Mar 2025$2.07B+2.7% $0.78-43.1% $137.00M6.6%
Dec 2024$2.08B+1.9% $0.18-88.5% $31.00M1.5%

From Solventum's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$8.32B+0.9% $8.88+221.7%18.7%
FY2024$8.25B+0.7% $2.76-64.6%5.8%
FY2023$8.20B+0.8% $7.79+0.1%16.4%
FY2022$8.13B— $7.78—16.5%

Frequently asked questions

When is Solventum's next earnings date?

Solventum has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Solventum earn last quarter?

For the quarter ended Sep 2026, Solventum reported diluted EPS of $-0.07 (-101.0% year over year) on revenue of $1.95B (-7.0%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.